SCHEMBL4332111

SCHEMBL4332111

O=C1CC[C@@H](C(=O)Nc2ccc3[nH]nc(-c4cc5ccccc5o4)c3c2F)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
PIP5K1C O60331 1/20 0.37
MAOB P27338 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
PARP1 P09874 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
POLB P06746 1/20 0.34
HPGDS O60760 1/20 0.34
TOP2A P11388 1/20 0.33
MAOA P21397 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341422 0.87 KDM4E (0.45) SMN1; SMN2KMT2ASIRT2SIRT1PIP5K1C
SCHEMBL4335335 0.83 MEN1 (0.48) SMN1; SMN2MEN1KMT2APARP1POLB
SCHEMBL4345714 0.81 MAPK10 (0.46) SMN1; SMN2MEN1KMT2ASIRT2SIRT1
SCHEMBL13198297 0.81 TOP2A (0.49) SMN1; SMN2MEN1KMT2ASIRT2SIRT1
SCHEMBL4341112 0.80 MEN1 (0.44) SMN1; SMN2MEN1KMT2APARP1POLB
SCHEMBL4336504 0.80 MEN1 (0.44) SMN1; SMN2MEN1KMT2APARP1POLB
SCHEMBL4334435 0.76 KMT2A (0.47) SMN1; SMN2MEN1KMT2ANPC1RAB9A
SCHEMBL2870047 0.74 MEN1 (0.45) SMN1; SMN2MEN1KMT2ANPC1RAB9A
SCHEMBL2864933 0.74 PIP5K1C (0.48) SIRT2SIRT1PIP5K1CMAOBNPC1
SCHEMBL2872600 0.73 KDM4E (0.45) MEN1KMT2ASIRT2SIRT1PIP5K1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SMN1; SMN2 4812/4885MEN1 3782/4885KMT2A 2212/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SMN1; SMN2 4812/4885MEN1 3782/4885KMT2A 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.